# US 2010/0166697 A1 · Combination therapy using tnf and alfa-galactosyl ceramide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0166697 A1
- Document ID: US20100166697A1
- Status: Published application
- Kind: A1
- Application number: 12/449,652
- Filed: 2008-02-20
- Published: 2010-07-01
- Earliest claimed: 2007-02-21
- Assignees: Vib Vzw; Universiteit Gent
- Inventors: Peter Brouckaert; Dirk Elewaut; Leander Huyghe
- Web page: https://patentgrep.com/patent/US20100166697A1

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 38/191: {Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.

## Claims

### Claim 1

A pharmaceutical composition comprising tumor necrosis factor (“TNF”) and alpha-galactosylceramide.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1 wherein the TNF is recombinant and human.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a chemotherapeutic agent.

### Claim 4

A method of treating cancer in a subject determined to be suffering therefrom, the method comprising:
administering tumor necrosis factor (“TNF”) and alpha-galactosylceramide to the subject in such a manner as to reduce the subject's tumor burden or eliminate the tumor burden in the subject so as to treat the cancer.

### Claim 5 (depends on 4)

The method according to claim 4 wherein a single alpha-galactosylceramide dose is administered to the subject at least one hour before administering TNF to the subject.

### Claim 6 (depends on 5)

The method according to claim 5 wherein TNF is administered daily to the subject for at least five (5) consecutive days.

### Claim 7 (depends on 2)

The pharmaceutical composition of claim 2, further comprising a chemotherapeutic agent.

### Claim 8 (depends on 4)

The method according to claim 4, wherein the TNF is recombinant and human.

### Claim 9 (depends on 4)

The method according to claim 4, further comprising administering a chemotherapeutic agent to the subject.

### Claim 10 (depends on 8)

The method according to claim 8, wherein a single alpha-galactosylceramide dose is administered to the subject at least one hour before administering TNF to the subject.

### Claim 11 (depends on 10)

The method according to claim 10, wherein TNF is administered to the subject daily for at least five (5) consecutive days.

### Claim 12 (depends on 9)

The method according to claim 9, wherein a single alpha-galactosylceramide dose is administered to the subject at least one hour before administering TNF to the subject.

### Claim 13 (depends on 12)

The method according to claim 12, wherein TNF is administered to the subject daily for at least five (5) consecutive days.

### Claim 14

In a method of treating a tumor in a mammal of the type comprising utilizing alpha-galactosylceramide to treat the tumor, the improvement comprising:
parenterally administering to the mammal, in addition to the alpha-galactosylceramide, from about 50 to about 300 μg/m2 of recombinant human tumor necrosis factor (“hTNF”),
wherein the administration of alpha-galactosylceramide and the administration of hTNF work synergistically with one another as to achieve a tumor reduction in the mammal.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the administration of hTNF to the mammal precedes the administration of alpha-galactosylceramide to the mammal.

### Claim 16 (depends on 14)

The method according to claim 14, wherein administration of alpha-galactosylceramide to the mammal precedes administration of hTNF to the mammal by at least one (1) day.

### Claim 17 (depends on 14)

The method according to claim 14, wherein administration of hTNF to the mammal proceeds for more than three (3) days.

### Claim 18 (depends on 17)

The method according to claim 17, wherein administration of hTNF to the mammal proceeds for more than five (5) days.

### Claim 19 (depends on 18)

The method according to claim 18, wherein administration of hTNF to the mammal proceeds for more than seven (7) days.

### Claim 20 (depends on 14)

The method according to claim 14, wherein the tumor is associated with carcinoma, melanoma, or lymphoma in the mammal.
